Summary
Abbott Laboratories (ABT) reported solid financial results for the second quarter and first half of 2019, demonstrating revenue growth and improved profitability. Net sales increased by 2.7% to $7.98 billion for the quarter and 2.4% to $15.51 billion for the six-month period, driven by strong performance across its key segments, particularly Cardiovascular and Neuromodulation, and Diagnostics. Excluding the impact of foreign exchange, sales growth was even more robust, highlighting the underlying operational strength of the company. Profitability saw a significant improvement, with operating earnings rising 36.7% to $1.21 billion in the quarter and 29.7% to $1.95 billion for the six months. This was supported by an increase in gross profit margin and controlled operating expenses. Diluted earnings per share (EPS) also saw a substantial increase, reflecting the strong operational performance and effective management of costs. The company continues to invest in research and development and shows a positive outlook, managing its debt effectively and returning capital to shareholders through dividends.
Financial Highlights
51 data points| Revenue | $7.98B |
| Cost of Revenue | $3.28B |
| Gross Profit | $4.22B |
| R&D Expenses | $577.00M |
| SG&A Expenses | $2.43B |
| Operating Expenses | $6.77B |
| Operating Income | $1.21B |
| Interest Expense | $168.00M |
| Net Income | $1.01B |
| EPS (Basic) | $0.57 |
| EPS (Diluted) | $0.56 |
| Shares Outstanding (Basic) | 1.77B |
| Shares Outstanding (Diluted) | 1.78B |
Key Highlights
- 1Net sales increased by 2.7% to $7.98 billion in Q2 2019 and 7.3% excluding foreign exchange, with the Cardiovascular and Neuromodulation segment leading growth.
- 2Total operating earnings saw a significant increase of 36.7% to $1.21 billion in Q2 2019, indicating improved profitability.
- 3Diluted Earnings Per Share (EPS) from continuing operations rose to $0.56 in Q2 2019, up from $0.40 in the prior year's quarter.
- 4The company's Diabetes Care business showed exceptional growth, with Freestyle® Libre sales increasing by 66.8% year-over-year.
- 5Gross profit margin improved to 52.8% in Q2 2019 from 50.5% in Q2 2018, driven by lower intangible amortization and restructuring costs.
- 6Abbott returned capital to shareholders by declaring quarterly dividends of $0.32 per share, an approximate 14% increase over the prior year's quarter.
- 7The company adopted the new lease accounting standard (ASU 2016-02) on January 1, 2019, which materially impacted the balance sheet by adding approximately $850 million in ROU assets and liabilities.